索磷布韦联合PR方案治疗慢性丙肝对患者肝损伤标志物、免疫因子及肝纤维化指标的影响

doi:10.3969/j.issn.1671-7171.2022.05.007

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1199 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨索磷布韦联合PR方案治疗慢性丙肝(CHC)对患者肝损伤标志物、免疫因子及肝纤维化指标的影响。【方法】入住两院的CHC患者134例,依据随机数字表法分为观察组与对照组,每组67例。对照组给予PR方案治疗,观察组给予PR方案联合索磷布韦治疗。观察两组治疗前后血清谷草转氨酶(AST)、谷丙转氨酶(ALT)、高尔基体蛋白73(GP73)、铁蛋白(SF)等肝损伤标志物水平;血清CD4⁺、CD8⁺、CD4⁺/CD8⁺等免疫因子水平;血清层粘连蛋白(LN)、透明质酸(HA)、3型前胶原蛋白(PCⅢ)、4型胶原蛋白(C-Ⅳ)等肝纤维化指标的变化及不良反应发生情况。【结果】治疗后,观察组血清AST、ALT、GP73及SF水平均低于对照组(P<0.05);观察组血清CD4⁺、CD4⁺/CD8⁺水平均低于对照组,CD8⁺水平高于对照组(P<0.05);观察组血清LN、HA、PCⅢ、C-Ⅳ水平均低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】索磷布韦联合PR方案治疗CHC可有效清除丙肝病毒,改善免疫因子水平,抑制肝纤维化,降低肝损伤标志物及肝纤维化指标水平,其疗效显著,且安全可靠。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	卓鑫
	裴媛媛

关键词 ：丙型肝炎,慢性, 抗病毒药/治疗应用, 肝/损伤, 免疫因子类, 肝硬化

Abstract：【Objective】 To investigate the effects of sothibuvir combined with PR regimen on liver injury markers, immune factors and liver fibrosis in patients with chronic hepatitis C (CHC). 【Methods】 A total of 134 patients with CHC admitted to the two hospitals were randomly divided into observation group and control group, with 67 cases in each group. The control group was treated with PR regimen, and the observation group was treated with PR regimen combined sothibuvir. The levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), Golgi protein 73 (GP73), ferritin (SF) and other markers of liver injury were observed before and after treatment; Serum CD4⁺, CD8⁺, CD4⁺/CD8⁺ and other immune factors; Changes of liver fibrosis indexes such as serum laminin (LN), hyaluronic acid (HA), type 3 procollagen (PCⅢ), type 4 collagen (C-Ⅳ) and occurrence of adverse reactions; 【Results】 After treatment, the levels of serum AST, ALT, GP73 and SF in the observation group were lower than those in the control group (P<0.05); The levels of serum CD4⁺, CD4⁺/CD8⁺ in the observation group were lower than those in the control group, and the level of CD8⁺ was higher than that in the control group (P<0.05); The levels of serum LN, HA, PCⅢ and C-Ⅳ in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Sorfosbuvir PR regimen combined with CHC can effectively eliminate Hepatitis C virus, improve the level of immune factors, inhibit liver fibrosis, and reduce the level of liver injury markers and indicators of liver fibrosis. It is effective, safe and reliable.

Key words： Hepatitis C, Chronic Antiviral Agents/TU Liver/SU Immunologic Factors Liver Cirrhosis

收稿日期: 2021-12-26

中图分类号:

R512.63

基金资助:陕西省科技厅项目(2021JM-472)

通讯作者: **E-mail:415288112@qq.com

引用本文:

卓鑫, 裴媛媛. 索磷布韦联合PR方案治疗慢性丙肝对患者肝损伤标志物、免疫因子及肝纤维化指标的影响[J]. 医学临床研究, 2022, 39(5): 664-666.
ZHUO Xin, PEI Yuan-yuan. Effects of Sothibuvir Combined with PR Regimen on Markers of Liver Injury, Immune Factors and Indicators of Liver Fibrosis in Patients with Chronic Hepatitis C. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 664-666.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.05.007 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I5/664

[1] ZHOU H, LU Y, WU B, et al. Cost-effectiveness of oral regimens for adolescents with chronic hepatitis C virus infection[J].Pediatr Infect Dis J,2020, 39(6):e59-e65.
[2] 童陆媛, 童照威, 钟剑锋, 等. 索磷布韦、达拉他韦联合利巴韦林对基因1b型慢性丙肝患者HCV RNA转阴率的影响[J].浙江中西医结合杂志, 2019, 29(9):735-737.
[3] 中华医学会肝病学分会,中华医学会感染病学分会.《丙型肝炎防治指南》2015年更新版[J].实用肝脏病杂志, 2016, 19(4):521-538.
[4] 付睿, 陆长春, 刘慧. 利巴韦林配伍PEG-IFNα-2a治疗对老年慢性丙肝患者血清可溶性Fas、FasL水平及T细胞亚群的影响[J].中国老年学杂志, 2019, 39(11):2664-2667.
[5] POORDAD F, SEDGHI S, POCKROS P J, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis[J].J Viral Hepat,2019, 26(8):1027-1030.
[6] 朱滢. 索磷布韦联合利巴韦林治疗慢性丙型病毒性肝炎的效果[J].南昌大学学报(医学版),2019, 59(3):64-67.
[7] TADA T, TOYODA H, YASUDA S, et al. Natural history of liver-related disease in patients with chronic hepatitis C virus infection:An analysis using a Markov chain model[J].J Med Virol,2019, 91(10):1837-1844.
[8] ABOUSHADY M, ALWASSIEF A, ABDELRAZIK M, et al. Retreatment of egyptian chronic hepatitis C patients not responding to pegylated interferon and ribavirin dual therapy[J].J Interferon Cytokine Res,2019, 39(9):539-546.
[9] URABE A, SAKAMORI R, TAHATA Y, et al. Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients[J].Hepatol Res,2019, 49(8):853-859.
[10] MOHAMED S Y, GABALLAH B A, MOHAMED ELSADEK H, et al. Resolved HBV behavior during the treatment of chronic HCV infection with direct-acting antivirals[J].Gastroenterol Hepatol Bed Bench,2019, 12(4):301-308.
[11] 万晓华, 刘向祎, 王凡, 等. 病毒性肝炎及肝癌患者血清GP73的表达及意义[J].海南医学, 2017, 28(23):3872-3874.
[12] 罗双艳, 钟丽坤, 张国, 等. 血清高尔基体蛋白73、血清诊断模型APRI及声辐射力脉冲成像技术在慢性乙型肝炎患者肝纤维化程度评估中的价值[J].广西医学, 2020, 42(5):525-528.
[13] 齐宁霞, 韦丽娟. 慢性乙型肝炎肝硬化患者血清铁蛋白(SF)水平变化及其临床价值[J].肝脏, 2019, 24(4):471-472.
[14] 游春芳, 周利民, 邓薇. 基因1b型慢性丙型肝炎患者血清铁蛋白水平与聚乙二醇干扰素抗病毒疗效的关系[J].临床肝胆病杂志, 2017, 33(9):1713-1716.
[15] 郝娟. 微生态制剂辅助恩替卡韦对HBV感染失代偿期肝硬化患者肝功能及肝纤维化指标改善的影响[J].抗感染药学, 2020, 17(5):751-753.